바이오인

 

 

 

The transformation of the original Voluntary Price Regulation Scheme, first agreed in 1957, into the modern PPRS began during Labour’s administration in the 1960s. An inquiry chaired by Lord Sainsbury established the principle of limiting the profits made on medicines supplied to the NHS by identifying the relevant capital employed, restricting the associated costs and limiting the allowable return.

 

The PPRS has remained a negotiated agreement between the ABPI and the Department of Health. However, the Department of Health has also published a new statutory scheme to control the prices of branded NHS medicines alongside the latest voluntary scheme.

 

Subsequent versions on the Pharmaceutical Price Regulation Scheme introduced progressively more sophisticated ways of regulating promotional spending and other costs, including those incurred outside the UK in relation to the production of NHS medicines. In
the early 1990s, the Scheme was further d to exclude the supply of generic medicines. This shift reflected NHS developments such as the creation of enhanced financial incentives for prescribers, practices and hospitals to minimise their medicine costs.

 

The 2005 Scheme increased the level at which companies routinely had to report financial data, eliminating some small companies from the whole process, except that their prices could only be increased after prior agreement with the Department of Health.

 

The 2009 Scheme contains a number of initiatives aimed at encouraging and rewarding innovation to continue to provide a choice of treatments for the benefit of patients and assisting the uptake of new medicines. The Department and the ABPI have agreed mechanisms on flexible pricing and patient access schemes which aim at better reflecting the value of medicines.

 

A new Statutory Scheme ? The Health Service Branded Medicines (Control Of Prices And Supply Of Information) (No. 2) Regulations 2008) ? is also in place for companies who are members of the voluntary PPRS.